The formation of a stable fibrin clot from fibrinogen involves three steps: 1) the removal of fibrinopeptides A and B to form fibrin monomer; 2) the self polymerization of fibrin monomer; and 3) the formation of covalent cross-links by Factor XIIIa. The first and third steps have been described in some detail (l), but the mechanism of polymerization remains unsolved. In an effort to understand this phenomenon, investigators have approached the problem at two levels. To understand the alignment of molecules which form the fibrin gel, techniques such as light scattering ( 2 , 3) or electron microscopy (4,5) have been used. The molecular basis for fibrin monomerfibrin monomer interactions has been approached by studying the binding of specific regions (binding sites) on the molecules. Complementary binding regions have been localized on the NH2-terminal and Fragment D domains of fibrinogen (6-13).
The formation of a stable fibrin clot from fibrinogen involves three steps: 1) the removal of fibrinopeptides A and B to form fibrin monomer; 2) the self polymerization of fibrin monomer; and 3) the formation of covalent cross-links by Factor XIIIa. The first and third steps have been described in some detail (l), but the mechanism of polymerization remains unsolved. In an effort to understand this phenomenon, investigators have approached the problem at two levels. To understand the alignment of molecules which form the fibrin gel, techniques such as light scattering ( 2 , 3) or electron microscopy (4,5) have been used. The molecular basis for fibrin monomerfibrin monomer interactions has been approached by studying the binding of specific regions (binding sites) on the molecules. Complementary binding regions have been localized on the NH2-terminal and Fragment D domains of fibrinogen (6-13).
The purpose of the present work was to localize and characterize a region of the fibrinogen molecule, specifically in the Fragment D region, which participates in the polymerization * This study was supported by Grant HL 14217 from the National Heart, Lung and Blood Institute of the National Institutes of Health, Bethesda, MD. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "aduertisenent" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. of fibrin monomer. Fragment Dl binds to insolubilized fibrin monomer and inhibits polymerization, but Fragments DS and D3 do not (7, 13). Therefore, it appeared that the binding site was removed during the conversion of Dl to D2. It was assumed that the amino acid sequence of the peptide, not conformation of the molecule, was responsible for the binding. In the present work a peptide released during the cleavage of Fragment Dl to DS was isolated. This peptide was tested for the ability to bind to. a thrombin-activated site on the NH2-terminal region of fibrinogen. It was also tested for the ability to inhibit fibrin monomer polymerization. The amino acid composition, NH2-and COOH-terminal sequences were determined in order to localize the peptide in the fibrinogen molecule. In this way, a fibrin polymerization binding site on the Fragment D region has been identified. 17) . Approximately 250 mg of the digest was gel filtered on a Sepharose CL-GB (Pharmacia) column (2.5 X 190 cm) in 0.1 M ammonium bicarbonate buffer, pH 7.6, to separate DI from a chain remnants and any higher molecular weight fragments. Fragments Dl and Ea cannot be separated by this technique; however, Fragment E3 is resistant to further digestion (18, 19) . The Fragment Dl preparation was dialyzed against 0.1 M ammonium bicarbonate, 0.025 M EDTA, pH 7.6, then digested (plasminogen, 10 units/g of Dl; streptokinase, 20,000 units/g of Dl) in the dialysis buffer at 37°C overnight. The preparation was freeze-dried and then resuspended in 10% acetic acid. The resulting Fragments D:j and Ea were separated from low molecular weight peptides by gel filtration on a Sephadex G-100 (Pharmacia) column (2.0 X 90 cm) in 10% acetic acid. The peptide solutions were freeze-dried, suspended in 0.1 M ammonium bicarbonate, pH 7.6, and further purified by affinity chromatography on insolubilized fibrin monomer. Fibrinogen was insolubilized on cyanogen bromide-activated Sepharose (Pharmacia) and converted to fibrin monomer by thrombin (human a-thrombin, kindly supplied by Dr. John W. Fenton 11, New York Department of Health, Albany, NY) as previously described (6). The Sepharose-fibrin monomer column (1 x 5 cm) was equilibrated in 0.1 M ammonium bicarbonate, pH 7.6, and peptide corresponding to 1.0 absorbance unit at 280 nm was applied to the column. Unbound material was removed by washing with the equilibration buffer, and bound peptide was eluted with 10% acetic acid. Approximately 4 0 8 of the applied peptide was capable of binding to the resin. The concentration of the purified peptide solution was determined by the method of Bradford (20).
MATERIALS AND METHODS

Isolation
Fibrinogen, fibrinogen digest, Fragments DI, D:r, and E were analyzed by polyacrylamide gel electrophoresis in 0.1% SDSI as described by Weber and Osborn (21) . Peptides were separated on 12.5% polyacrylamide SDS gels according to the method of Swank and Munkres (22) . Gels were stained by the method of pH 7.8, was incubated with 1 mCi of carrier-free Na'"1 (New England Nuclear) and 1 mg of chloramine-T for 30 s a t room temperature.
The reaction was stopped by the addition of 1 mg of sodium metabisulfite followed by gel filtration of the preparation on a Bio-Gel P-2 (Bio-Rad) column (0.6 X 30 cm) in 10% acetic acid.
Inhibition of Fibrin Monomer Polymerization-Fibrin monomer was prepared according to the method of Belitser and colleagues (25) using either thrombin or batroxobin (enzyme from the venom of Bothrops atrox, Pentapharm, Basel, Switzerland). Polymerization was measured spectrophotometrically a t 350 nm as described (26) . T o measure the effect of Dl peptide on the rate of thrombin fibrin monomer polymerization, a 0.19-ml aliquot of either 0.05 M Tris-HCI.
0.1 M NaCI, pH 7.55, or 0.19 ml of the buffer containing the peptide was put into a quartz cell, and the base-line was recorded. At zero time the recorder was started, and 0.01 ml of fibrin monomer (1.5 mg/ ml in 0.02 M acetic acid) was added, the cells were inverted, and the increase in absorbance a t 350 nm was measured continuously for 15 min or until plateau levels were reached. For batroxobin fibrin monomer 0.15 ml of buffer or buffer containing peptide was mixed with 0.05 ml of batroxobin fibrin monomer (1.5 mg/ml in 0.02 M acetic acid). The initial rate of polymerization was calculated from the slope of the steepest part of the curve and expressed as the increase in absorbance per min (A:l~d,.min-l).
In some experiments the concentration of batroxobin fibrin monomer was varied to calculate the effect of concentration on initial velocity. In these cases the amount of batroxobin fibrin monomer varied from 0.05 ml to 0.02 ml in a final volume of 0.2 ml.
Equilibrium Binding of Dl Peptide-NHZ-terminal disulfide knot was prepared from a cyanogen bromide digest of fibrinogen as described (18, 27) . NDSK (10 mg) was dialyzed against 0.15 M Tris-HCI, 10 mM calcium chloride, pH 7.8, then incubated with 10 units of thrombin for 4 h a t 37°C. Under these conditions both fibrinopeptides A and B are removed as determined by analysis of the NH?-terminal amino acids (28) (29) (30) . Equilibrium dialysis was done in small test tubes usingstandard dialysis tubing (Arthur H. Thomas). NDSK, thrombintreated NDSK, fibrinogen, or Fragment Dl in final concentrations ranging from 4.4 X lo-' M to 2 X 10 -" M in 0.5 ml of 0.15 M Tris-HCl, pH 7.8, was dialyzed against 1.0 ml of buffer containing 1Z51-labeled Dl peptide (4.4 x lo-' M to 2 x M final concentration) at room temperature for 18 h. The volumes of solutions inside and outside the tubing were quantitated, and aliquots were counted (y-counter, Nuclear-Chicago). Results were verified using the Sephadex gel equilibration procedure of Hirose and Kano (31) using Sephadex G-25 (Pharmacia) prewashed with 50% acetic acid, distilled water, and ethanol, then dried. In conical centrifuge tubes 0.1 mg of dry Sephadex G-25 was reswollen in 0.75 ml of 0.15 M Tris-HCI, pH 7.4, containing 1.0 mg/ml of bovine serum albumin. Binding data from equilibrium dialysis and gel equilibration procedures were analyzed according to the Scatchard equation (32). Binding experiments with Fragment Dl, NDSK (untreated, thrombin treated, and batroxobin treated), and with fibrinogen were done similarly.
The stoichiometry of binding of Dl peptide to thrombin or batroxobin fibrin monomer was examined by the gel equilibrium procedure. Conditions were established such that the polymerization of fibrin monomer was inhibited by the DI peptide. In a final volume of 1.0 ml. thrombin or batroxobin fibrin monomer (1 X 10" M final concentration) was mixed with '"I-labeled Dl peptide (2 X lo-" M to 2 X 10 '' M final concentration) which was pre-equilibrated in Sephadex G-25 swollen in 0.05 M Tris-HCI, 0.1 M NaCI, pH 7.55. The molar ratio of peptide to fibrin monomer in each experiment was greater than 100 to 1. The amount of bound peptide was calculated according to the method of Hirose and Kano (31) .
TotaIAmino Acid Composition-Approximately 50 nmol of the Dl peptide in the presence of 50 nmol of norleucine were hydrolyzed in 0.2 ml of concentrated hydrochloric-propionic acid (Pierce) under vacuum a t 1 10°C for 24,48. and 72 h. The hydrolysate was analyzed in an automatic amino acid analyzer (Beckman, model 119). The concentration of each amino acid was calculated by extrapolation of the concentrations a t various hydrolysis times.
NH2-terminaI Amino Acid Sequence-This was determined by the method of Edman and Henschen (33) with the modifications of Tarr (34). The phenylthiohydantoin derivatives were analyzed on polyamide sheets (Chen Chin Trading Co., Taiwan), 5 X 5 cm, according to the method of Kulbe (35, 36) with the modifications of Summers et al. (37) . Standard phenylthiohydantoin derivatives were a generous gift from Dr. Vern L. Schramm of this institution.
COOH-terminal Amino Acid Sequence-This was determined by sequential removal of amino acids from the carboxyl-terminal end (38-40) using carbox.ypeptidase Y (Worthington). Approximately 25 nmol of peptide were incubated with carboxypeptidase Y (100:1, w/ w) in 0.1 M sodium acetate buffer, pH 5.0, a t room temperature for various times. The reaction was stopped by heating at 100°C for 3 min. The material was freeze-dried, dissolved in 0.2 M sodium citrate buffer, pH 2.2, filtered, and applied to the amino acid analyzer.
RESULTS
Preparation of Dl Peptide-Fibrinogen was digested with plasmin to obtain primarily Fragments Dl and E:l. The Fragment Dl which was isolated by gel filtration consisted of three polypeptide chains a, / 3 , and y, of molecular weights 12,000, 43,000, and 39,000, respectively, as seen on 7% polyacrylamide gel electrophoresis under reducing conditions (Fig. 1) (Fig. 1 ). Peak I was tested on 7% polyacrylamide (SDS) gels, and Peaks I1 and I11 were analyzed on 12.5% polyacrylamide (SDS) gels. Peak I1 contained a t least four peptides while Peak I11 contained two peptides of approximate molecular weights 5,000 and 5,500. Affinity chromatography of peptides from Peaks I1 or I11 on Sepharose-insolubilized fibrin monomer bound approximately 8% or 40%, respectively, of the 
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protein. On 12.5% polyacrylamide gel electrophoresis of the bound material from either peak, a single band of M, approximately 5,000 was seen (Fig. 2) . This I l l peptide was labeled with ' "1 by the chloramine-T method (24). An aliquot of the labeled peptide was electrophoresed on 12.5% polyacrylamide gels which were sliced and counted (Fig. 2) . A single band of radioactivity which corresponded in mobility to the M, = 5000 peptide was present. The Dl peptide isolated by affinity chromatography on insolubilized fibrin monomer was suspected to originate from the y chain of the Fragment D region of fibrinogen and has an affinity for fibrin monomer. ' 5 ' lnce Fragment Dl binds to fibrin monomer but Fragments D:! and Da do not (7, 13, 42) . it is possible that the Dl peptide may contain the binding site responsible for the interaction of fibrin monomer and Fragment Dl.
Inhibition of Fibrin Monomer Polymerization-The pol-ymerization of fibrin monomer which was formed by batroxobin (lacking fibrinopeptide A) or by thrombin (lacking fibrinopeptides A and B) was inhibited by the Dl peptide. As the molar ratio of peptide to fibrin monomer increased, the maximum rate and extent of polymerization at 15 min decreased proportionally, while the lag time increased (Fig. 3) . The effect of the Dl peptide on the maximum rate of thrombin or batroxobin fibrin monomer pol-ymerization at various molar ratios indicated that the maximum rate of polymerization was decreased by 50% at approximately a 1:l molar ratio (Fig. 4) . The data indicate that the Dl peptide interacts with fibrin monomer at a binding site that becomes available on the fibrin monomer after the cleavage of fibrinopeptide A and that two molecules of the peptide combine with one molecule of fibrin monomer. In order to asses the effect of the Dl peptide on fibrin monomer pol-ymerization over a wide range of concentrations, batroxobin fibrin monomer concentration was varied from 3.3 X lo-" M to 1.75 X lo-' M and the maximum rate of polymerization measured in the absence or presence of 2.5 X lo-' M Dl peptide (Fig. 5) . The pol-ymerization of fibrin monomer appears to resemble a condensation reaction since, as i t s concentration increases, the Vn,ax and K,, values approach infinity. Therefore, the measure of inhibitory potential or K, of the Dl peptide cannot be derived from the kinetic data. The effect of the peptide is to decrease the apparent concentration of polymerizable species of fibrin monomer. For example, to achieve a maximum rate of 0.2 A:,HI-min-l, the concentration of batroxobin fibrin monomer is 7.8 X lo-' M. However, at a peptide concentration of 2.5 X lo-' M, the concentration of fibrin monomer necessary to achieve the same rate of polymerization (apparent [FM] ) is 1.42 X lo-' M. Therefore, the peptide appears to decrease the concentration of fibrin monomer and acts as a competitive inhibitor of polymerization.
Equilibrium Binding of Dl Peptide-The Dl peptide bound to Sepharose-insolubilized fibrin monomer but not to insolubilized fibrinogen. Therefore, it appeared that the peptide bound to a site on the NH2-terminal region of fibrinogen which is revealed by thrombin. To measure the number of binding sites and the strength of the interaction, the binding of the Dl peptide to NDSK, thrombin-treated NDSK, fibrinogen, fibrin monomer, and Dl was tested. Binding studies were done using either the classical equilibrium dialysis technique with dialysis tubing in small test tubes or the Sephadex gel equilibrium technique (31) . In the latter technique, ' "1 D l peptide was incubated with Sephadex G-25 for 15 min at which time equilibrium was achieved. The species to be tested was added and equilibrium again established. An aliquot of the supernatant was removed and counted. The outside volume was determined using 1251-fibrinogen. The amounts of bound and free peptide were calculated according to Hirose and Kano (31) . The data were analyzed by the Scatchard method (32). In the Sephadex gel method equilibrium is established very quickly, usually within 10 min, a feature which allowed some experiments to be done testing the interactions of D l peptide with fibrin monomer. For NDSK, thrombin-treated NDSK, fibrinogen, and Fragment Dl, results from the two methods, equilibrium dialysis and Sephadex gel equilibrium, were comparable.
NDSK is a cyanogen bromide fragment of fibrinogen which contains the intact NH2-terminal region of all six polypeptide chains. Since this fragment does not self polymerize, it was used as a tool to measure the binding of D l peptide to the NH2-terminal region of fibrinogen after thrombin treatment. There was no measurable binding of the Dl peptide to intact NDSK, to fibrinogen, to Fragment Dl, or to the bovine serum albumin. However, the peptide bound to NDSK which was pretreated with thrombin to remove fibrinopeptides A and B. The data (Fig. 6) indicate that there are approximately 2.1 binding sites on thrombin-treated NDSK with a Ka of 1.45 X M. Since the Scatchard method of data analysis has the dependent variable on both the x and y axes, the data were replotted as l/free ligand uersus total NDSK/bound protein.
The parameters obtained from this plot were 2.2 for n, and 1.6 X M for Ka. The purification of NDSK involves incubation of fibrinogen in cyanogen bromide in the presence of 70% formic acid. This treatment may alter the binding sites. Therefore, an attempt was made to reproduce the data using fibrin monomer instead of thrombin-treated NDSK. A major difficulty, the self-polymerization of fibrin monomer, was overcome by using high molar ratios of peptide to fibrin monomer. However, in this situation the concentration of peptide could be varied only over a small range of concentrations. Dl peptide was added to the Sephadex gel equilibrium system and incubated for 10 min and, then soluble fibrin monomer was added in a molar excess of peptide to fibrin monomer of 100-to 1000-fold. Under these conditions the lag time in the fibrin monomer polymerization was more than 30 min.
After 10 min of incubation an aliquot of the supernatant was removed and counted. From these data the number of binding sites on the fibrin monomer molecule could be calculated. However, since the concentration of peptide could be varied only within one order of magnitude as the peptide was acting as a competitive inhibitor of the native site on the D region of fibrin monomer, the dissociation constant could not be derived. In experiments using thrombin fibrin monomer Table I , are compared to the amino acid composition of the COOH-terminal segment of the y chain 373-410 (43, 44).
The conversion of Fragment Dl to Ds results in cleavages in the COOH-and NH-terminal regions of the y chain remnant (7, 42). Thus, the Dl peptide could originate from either of these two regions. The NHz-terminal end of the y chain has a large region devoid of glycine between residues 24 and 150. Also, there are no phenylalanine residues between position 28 and 168 in the y chain. Since the D L peptide contains 1 phenylalanine and 6 glycine residues, it is probable that the peptide originated from the COOH-terminal end of the y chain. The presence of a valine in the peptide suggests that it may extend to the terminal residue, 410 valine, of the y chain. for 30 min, 1,2,3,4 , or 5 h. For controls, carboxypeptidase Y was incubated similarly but without the Dl peptide, to measure autolysis of the enzyme. The zero time control was obtained by adding peptide and enzyme to boiling buffer. The concentration of each amino acid was calculated, then background and zero time levels were subtracted. The release of the amino acids at each time point is illustrated in Fig. 7 . The data indicate that the COOHterminal sequence of the peptide is Ala-Gly-Asp (or Am)-Val, corresponding to residues 407-410 of the fibrinogen y chain. The entire sequence of the Dl peptide based on the published sequence of the y chain (43, 44) is shown in Fig. 8 . (45-49) . The removal of fibrinopeptide A by thrombin proceeds at a much faster rate than that of fibrinopeptide B (50); however, the removal of fibrinopeptide A is sufficient for polymerization to occur (51).
Ferry (2) postulated that polymerization of fibrin monomer molecules takes place through two processes, initially by an end-to-end association of molecules forming a fibrin strand and secondarily, by a lateral association of the strands. Steiner and Laki (52) used light scattering to differentiate between the two steps in polymerization. Recently the same technique was used to demonstrate that the removal of fibrinopeptide A led to the polymerization of fibrin monomers to form protofibrils and that the effect of the removal of fibrinopeptide B is an enhancement of the rate of lateral association of protofibrils (3).
Recent investigations have focused on defining areas of the fibrin monomer molecule that participate in polymerization by identifying binding properties of degradation products of fibrinogen or fibrin. Fibrinogen and fibrin monomer insolubilized on cyanogen bromide-activated Sepharose allowed the localization of complementary binding regions on the Fragment D and on the NHz-terminal domain of fibrin (6-13). The NHz-terminal site appears to be revealed or activated by the loss of the fibrinopeptides (8, 13). It was shown that abnormal fibrinogen Detroit had a functional binding site in the Fragment D domain but had a defective site in the NHn-terminal region (53). This fibrinogen variant contains a single amino acid substitution, Aa, 19 Arg --j Ser, suggesting the NH2-terminal binding site is at or near residue 19 on the Aa chain (53). Recently, evidence was provided that the tripeptide GlyPro-Arg which is contiguous with fibrinopeptide A binds to fibrinogen and inhibits fibrin monomer polymerization (11, 12). This suggests that an NHs-terminal binding site is located on the Aa chain of fibrinogen immediately following fibrinopeptide A. It has been postulated that the Fragment D binding site is located on either the NHz-terminal or COOH-terminal region of the y chain remnant of Fragment D (7,42) . In the present work a peptide from the COOH-terminal region of the y chain has been isolated ( Figs. 1 and 2) . This peptide encompasses residues 373-410 in the y chain (Figs. 7 and 8, Table I ) and can inhibit the polymerization of thrombin or batroxobin fibrin monomer (Figs. 3-5) . It can also bind to a thrombinactivated site on the NHs-terminal region of fibrinogen as shown by the binding to thrombin-treated NDSK or to fibrin monomer (Fig. 6) . The Kd for the binding of the DL peptide to thrombin-treated NDSK, 1.45 X M, indicates a fairly tight association. In comparison, the K d for the binding of the peptide Gly-Pro-Arg-Val (a 17 Gly-20 Val) to fibrinogen was on the order of 1 X M (11, 12). The Dl peptide may be capable of an increased number of interactions due to the increased length of the peptide. NDSK is prepared after treatment with cyanogen bromide in 70% formic acid, rather harsh conditions, and it is not known what effect this may have on the affinity for the peptide. However, the ability of the Dl peptide to inhibit fibrin monomer polymerization at relatively low concentrations suggests that the affinity of the peptide for fibrin monomer may be underestimated in comparison to NDSK. Since there are two binding sites for the peptide on both thrombin and batroxobin fibrin monomer, it appears that the complementary NH2-terminal site is revealed by the loss of fibrinopeptide A alone. This suggests that the binding site on the Dl peptide is a site involved in the initial steps in polymerization, probably in the end-to-end polymerization of fibrin monomers, forming protofibrils (3).
The high affinity of the Dl peptide for NDSK and fibrin monomer implies that the amino acid sequence may be solely required for a binding function of this polymerization site. In the fibrinogen molecule the D site on the COOH-terminal end of the y chain must be exposed to the surface to allow easy access of complementary fibrin monomer molecule for polymerization. The location of this polymerization site in such close proximity of the y chain cross-linking sites supports the hypothesis that three fibrin monomer molecules are necessary to get a y-y dimer (13). In this model, when two fibrin monomers align, the COOH-terminal end of the y chain (D site) of the fist molecule binds to the NHn-terminal binding site on the second molecule. In this position the y chains of the two molecules are far apart and could not cross-link. When a third molecule joins the dimer, its y chain COOH-terminal region binds to the a chain of the second molecule. Now the COOH-terminal region of the y chains of the first and third molecules are held in close proximity and cross-linking could
In conclusion, a polymerization site resides within the COOH-terminal sequence of the y chain, 373-410. This site has high affinity for fibrinopeptide-depleted NH2-terminal region of the fibrinogen molecule. The purified Dl peptide contains the functionally active site, and it is a potent competitive inhibitor of the fibrin polymerization reaction.
occur.
